期刊文献+

CYP3A5基因多态性对临床药代动力学影响的研究进展 被引量:5

原文传递
导出
摘要 目的阐述细胞色素P450 3A5基因多态性对临床药代动力学影响的研究进展。方法分析、归纳、总结发表的文献。结果与结论药物基因组学通过研究基因表达水平及单核苷酸多态性与临床药代动力学或药物毒性的相关性,增加药物的有效性和安全性,减少不良反应,因而受到广泛研究,取得了重要的进展。细胞色素P450 3A5基因的遗传多态性存在明显的个体差异,对不同个体的药物治疗作用和不良反应及药物的毒性产生重要影响,是引起个体及种族间对同一底物代谢能力不同的原因之一。目前对该基因多态性与临床药代动力学的研究主要集中在大环内酯类抗生素、抑制胃酸用药、保肝及肝病辅助药、调节血脂药、镇静催眠及抗焦虑药、免疫调节剂等药以及其他药物。
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第20期1541-1545,共5页 Chinese Pharmaceutical Journal
  • 相关文献

参考文献39

  • 1RUF HH, WENDE P, ULLRICH V. Models for ferric cyto- chrome P550. Characterization of hemin mercaptide complexes by electronlc and E SR spectral [J]. J lnorg Biochem, 1979,11 (3) : 189 -204.
  • 2KLINGENBERG M. Pigments of rat liver microsomes [ J ]. Arch Biochem Biophys, 1958,75 (2) : 376-386.
  • 3RENDIC S. Summary of information on human CYP enzymes: hu- man P450 metabolism data [ J ]. Drug Metab Rev, 2002,34 ( 1 - 2) : 83-448.
  • 4WILLIAMS J A, RING B J, CANTRELL V E, et al. Compara- tive metabolic capabilities of CYP3A4, CYP3AS, and CYP3A7 [J]. Drug Metab Dispos,2002,30( 8 ) : 883-891.
  • 5LIN Y S, DOWLING A L, QUIGLEY S D, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intesti- nal midazolam metabolism [ J ]. Mol Pharmacol, 2002,62 ( 1 ) : 162-172.
  • 6JOUNAIDI Y, HYRAILLES V, GERVOT L, et al. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expres- sion of the protein[ J]. Biochem Biophys Res Commun, 1996,221(2) : 466-470.
  • 7XIE H G, WOOD A J, KIM R B, et al. Genetic variability in CYP3A5 and its posslble consequences[ J]. Pharmacogenomics, 2004,5(3) : 243-272.
  • 8BUSI F, CRESTEIL T. CYP3A5 mRNA degradation by non- sense-mediated mRN A decay [ J ]. Mol Pharmacol,2005,68 (3) : 808-815.
  • 9LANGAEE T Y, GONG Y, YARANDI H N, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil[ J ]. Clin Pharmacol Ther , 2007,81( 3 ) : 386-391.
  • 10刘亮,杨琳,张艳超,艾晓非,王建祥,肖志坚.汉族人群药物代谢酶基因多态性位点基因型分布频率的研究[J].中华医学杂志,2009,89(38):2675-2681. 被引量:11

二级参考文献116

共引文献43

同被引文献58

  • 1陈伦,唐跃年,张健.高效液相梯度洗脱法测定尿液中6β-羟基氢化可的松和氢化可的松的含量[J].中国药师,2006,9(4):331-333. 被引量:6
  • 2田志松.高效液相色谱-二极管阵列法同时检测尿中内源性氢化可的松及其代谢产物[J].中国药房,2006,17(16):1235-1237. 被引量:6
  • 3陆晓彤,张顺国,张健,蒋樾廉.上海地区208名儿童CYP3A活性分布[J].中国医院药学杂志,2007,27(3):336-339. 被引量:2
  • 4Lee J,Huang HF,Chen Y, et al. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients [ J ]. Biopharm. Drug Dispos ,2014,35 (3) : 164 - 172.
  • 5Miao LY,Huang CR, Hou JQ, et al. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentra- tion and dose requirements in Chinese renal transplant recipients [ J ]. Biopharm Drug Dispos,2008,29 ( 1 ) : 1 - 5.
  • 6Anglichean D, Cone DL, Lechaton S, et al. Consequences of ge- netic polymorphisms for sirolimus requirements after renel trans- plant in patients on primary sirolimus therapy [ J ]. Am J Trans- plant,2005,5 (3) :595 - 603.
  • 7Zochowska D, WyzgaCJ, Pczek L. Impact of CYP3A4 * 1B and CYP3A5 * 3 polymorphisms on the pharmacokinetics of cycIospo- fine and sirolimus in renal transplant recipients [ J ]. Ann Trans- plant,2012,17 (3) :36 -44.
  • 8Mourad M,Mourad G,Wallemacq P, et al. Sirolimus and taemli- mus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids [ J ]. Transplantation,2005,80 (7) :977 - 984.
  • 9Meur YL, Djebli N, Szelag JC. CYP3A5 * 3 influences sirolimus oral clearance in de novo and stable renal transplant recipients [ J ]. Clin Pharmacol Ther, 2006,80 ( 1 ) :51 - 60.
  • 10Lamba JK, Lin YS, Thummel K, et al. Common allelic variants ofcytochrome P4503A4 and their prevalence in different populations [J]. Pharmacogenetics, 2002,12(2) , 121-132.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部